mRNA Technology Newsletter
Issue #62November 9, 20267 studies

A single CRISPR infusion cut LDL by ~45% in primates — and held for 3 years

mRNA and gene-editing research had a productive week — not in a vague, promising-future-ahead way, but in a concrete, numbers-on-the-board way.

From a one-shot cholesterol fix that lasted three years in primates to a PEG workaround that triples mRNA expression after repeat dosing, here's what actually moved the needle.

One shot, three years of lower cholesterol 🧬

  • Researchers delivered a CRISPR adenine base editor — packaged in a GalNAc-lipid nanoparticle — that targets ANGPTL3, a gene that drives up LDL and triglycerides. A single infusion in nonhuman primates knocked circulating ANGPTL3 protein down by more than 90%, with effects confirmed out to three years post-dose.
  • In hyperlipidemia animal models, LDL dropped roughly 40–50% and triglycerides fell 50–70%. Editing was liver-selective, and off-target analysis across ~3,000 candidate sites found no detectable edits or structural variants.
  • The study has now seeded a first-in-human trial in patients with refractory hyperlipidemia syndromes.

Why it matters: Most cholesterol drugs require daily or monthly dosing forever. A single-course edit that holds for years — if it translates to humans — would fundamentally change how chronic cardiovascular risk is managed.

🔗 Nature Journal Article 🗓️ Nov 6

Key Findings

The PEG problem in repeat-dose mRNA vaccines has a fix — maybe 💉

  • Antibodies can complicate repeat dosing. Researchers tested an alternative carrier in mice.
  • The animal study found differences in how immune cells responded. Human studies would be needed to establish a clinical advantage.
💡 PEG alternatives may rescue mRNA drugs that lose punch after repeat doses.
🥈 Top 2% journal 🔗 ACS nano Journal Article 🗓️ Nov 3

mRNA delivered to the brain — including in a primate 🧠

  • Researchers detected delivery to brain tissue in animal models, including a nonhuman primate.
  • The investigators also reported reduced injury in a mouse model. The study provides preclinical evidence.
💡 Brain-targeted mRNA delivery now has a non-human primate proof of concept.
🥇 Top 1% journal 🔗 Nature nanotechnology Journal Article 🗓️ Nov 3

A gut-delivered mRNA therapy reshaped immune cells in human tissue 🔬

  • Glucocorticoid-derived lipid nanoparticles (MP2 LNPs) delivered mRNA rectally in mice with colitis, showing 15-fold higher efficiency than the FDA-approved SM102 formulation. Treated mice had preserved colon length and reduced inflammatory signals.
  • Crucially, the team tested MP2 LNPs in biopsies from actual IBD patients — and saw meaningful shifts in regulatory versus inflammatory T cell populations, a rare step toward human-relevant validation.
💡 Steroid-derived LNPs hit inflamed gut tissue harder than current clinical-grade nanoparticles.
🥈 Top 2% journal 🔗 Nature communications Journal Article 🗓️ Nov 4

A universal flu vaccine candidate that actually covers decades of drift 🦠

  • Self-amplifying mRNA vaccines encoding computationally engineered influenza H5 antigens — representing both major phylogenetic groups and multiple neuraminidase subtypes — generated broad protection in mice and ferrets against H5N1 strains spanning two decades of evolution.
  • Compared to WHO candidate vaccine viruses, the computationally designed multivalent approach (DVX-panH5Nx) showed superior cross-clade protection, with efficacy at doses as low as 0.4 µg in influenza A models.
💡 Computationally designed flu vaccines outperformed WHO reference strains across two decades of viral drift.
🥈 Top 2% journal 🔗 Cell reports. Medicine Journal Article 🗓️ Nov 5

Frailty quietly undermines mRNA vaccine responses in older adults 👴

  • A Lancet Healthy Longevity review examined COVID-19 mRNA vaccine data and found that frailty — through immunosenescence, chronic inflammation, and impaired innate and adaptive immune function — is associated with weaker and less durable vaccine responses compared to non-frail peers.
  • The review argues that LNP composition, dosing, and mRNA cargo could all be tuned for frailty, but frailty-specific trial data remain scarce, making firm recommendations premature.
💡 Frailty may be a hidden variable explaining why some older adults respond poorly to mRNA vaccines.
🥇 Top 1% journal 🔗 The lancet. Healthy longevity Review 🗓️ Nov 3

mRNA vaccines boosted T cell therapy against brain tumors in mice 🎯

  • In glioblastoma mouse models, an mRNA vaccine encoding a tumor antigen drove expansion of adoptively transferred T cells to up to 80% of circulating CD8+ T cells — and improved tumor infiltration in the brain.
  • The approach was extended to a human glioblastoma antigen (PTPRZ1), where mRNA-transfected dendritic cells combined with matched T cell therapy led to rejection of implanted primary human glioma cells expressing that antigen.
💡 mRNA vaccines may give adoptive T cell therapies the in-vivo boost they need to reach brain tumors.
🥈 Top 2% journal 🔗 Cancer research Journal Article 🗓️ Nov 4

Implications

The through-line this week: delivery is no longer the bottleneck it was five years ago. Brain, gut, platelets, lymph nodes — mRNA is reaching them. The unresolved tension is durability: most expression windows are transient by design, and for chronic diseases, that means repeat dosing — which is exactly where anti-PEG immunity and immune tolerance start to complicate everything.

Studies in this issue

Primary sources used for this newsletter.

  1. Wide vaccine protection against different global influenza A/H5Nx virus strains
    key findingCell reports. Medicine2026-11-05PMID 42987826
  2. Designing fat-based nanoparticles to deliver RNA medicines to the brain
    key findingNature nanotechnology2026-11-03PMID 42977805
  3. How Frailty May Affect mRNA Vaccine Effectiveness
    key findingThe lancet. Healthy longevity2026-11-03PMID 42976900